Former Shire CEO shakes up Galderma as IPO decision looms

Flemming Ørnskov is "doubling down on science" and readying Galderma, formerly owned by Nestle, for competition with the likes of Sanofi.

Photo: Shire/ PR

Flemming Ørnskov led Shire's expansion into rare diseases before the drugmaker's USD 62bn (DKK 399.3bn) sale to Takeda Pharmaceutical Co. in 2019. Now he's plotting a new course for a skincare business that Nestle SA gave up on.

Ørnskov, who took the reins of Switzerland-based Galderma two years ago, said in an interview that he's "doubling down on science," accelerating research spending and adding dermatologists and medical specialists as the company prepares for a potential initial public offering.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs